This dual mechanism, combining PD-1/PD-L1 blockade and ADCC, may offer superior outcomes compared to traditional PD-1 inhibitors by providing a broader and more sustained anti-tumor response, especially in tumors with poor T cell infiltration or immune evasion. The gene discussed is CD274; the disease is neoplasm.